rs372497906
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_003907.3(EIF2B5):c.1265G>A(p.Arg422Gln) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000545 in 1,614,044 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 16/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_003907.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
EIF2B5 | NM_003907.3 | c.1265G>A | p.Arg422Gln | missense_variant | 8/16 | ENST00000648915.2 | NP_003898.2 | |
EIF2B5 | XM_047449148.1 | c.1265G>A | p.Arg422Gln | missense_variant | 8/11 | XP_047305104.1 | ||
EIF2B5 | XM_011513265.1 | c.515G>A | p.Arg172Gln | missense_variant | 4/12 | XP_011511567.1 | ||
EIF2B5 | XM_011513266.4 | c.428G>A | p.Arg143Gln | missense_variant | 3/11 | XP_011511568.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
EIF2B5 | ENST00000648915.2 | c.1265G>A | p.Arg422Gln | missense_variant | 8/16 | NM_003907.3 | ENSP00000497160.1 |
Frequencies
GnomAD3 genomes AF: 0.0000986 AC: 15AN: 152160Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000278 AC: 7AN: 251478Hom.: 0 AF XY: 0.0000441 AC XY: 6AN XY: 135908
GnomAD4 exome AF: 0.0000499 AC: 73AN: 1461884Hom.: 0 Cov.: 33 AF XY: 0.0000523 AC XY: 38AN XY: 727244
GnomAD4 genome AF: 0.0000986 AC: 15AN: 152160Hom.: 0 Cov.: 32 AF XY: 0.000121 AC XY: 9AN XY: 74336
ClinVar
Submissions by phenotype
Vanishing white matter disease Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 16, 2018 | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. - |
Uncertain significance, criteria provided, single submitter | clinical testing;provider interpretation | Geisinger Autism and Developmental Medicine Institute, Geisinger Health System | Aug 10, 2017 | This is a 4 year old male with a history of developmental delays, autism spectrum disorder, and sleeping difficulties. Overall, he does not have dysmorphic features, but occipital flattening was noted. He is a compound heterozygote for 2 VUSs in EIF2B5 gene (p.Leu117Val and p.Arg422Gln), which are in trans. The p.Arg422Gln variant is present in gnomAD at 0.005% in the European Non-Finnish population and computational models predict this variant is not likely to alter the protein structure/function. This patient does not have the clinical features we would associate with a leukoencephalopathy, though he has not had an MRI. Additionally, whole exome sequencing also identified two additional variants of uncertain significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 13, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jun 19, 2022 | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 422 of the EIF2B5 protein (p.Arg422Gln). This variant is present in population databases (rs372497906, gnomAD 0.005%). This variant has not been reported in the literature in individuals affected with EIF2B5-related conditions. ClinVar contains an entry for this variant (Variation ID: 560269). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt EIF2B5 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Inborn genetic diseases Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 20, 2021 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at